NewcelX wins Brazil patent for NCEL-101 manufacturing process through 2036 - NCEL News | RalliesNewcelX wins Brazil patent for NCEL-101 manufacturing process through 2036
N
NCEL• Brazil patent extends NCEL-101 process coverage
- NewcelX received a Brazilian patent covering its cell selection and enrichment manufacturing process for NCEL-101 in type 1 diabetes.
- Patent BR 112018010946-0 runs to November 2036, extending IP coverage in a large Latin American diabetes market.
- The program is moving toward clinical trials following an FDA Type B Pre-IND meeting for NCEL-101 with Eledon’s anti-CD40L antibody tegoprubart.
•
